Search Results - john+toscano

16 Results

Sort By:

Alkylsulfenyl Thiocarbonates as Precursors to Hydropersulfides

Unmet Need:According to a survey by the CDC, nearly 50% of Americans age 20 and up have some form of cardiovascular disease (see AHA). The management of cardiovascular diseases depends on the specific indication, and standard therapies include one or multiple of the following types of medications: blood thinners, ACE inhibitors, beta-blockers, calcium...

Published: 5/10/2024 | Inventor(s): John Toscano, Vinayak Khodade, Sahil Aggarwal, Nazareno Paolocci, Blaze Pharoah, Gizem Keceli, Kelsey Zhang

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Clinical and Disease Specializations > Oncology

N-Acyloxysulfonamide and N-Hydroxy-N-acylsulfonamide Derivatives as Stabilized HNO Donors

Technology OverviewThe invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions...

Published: 5/9/2024 | Inventor(s): Art Sutton, Stephen Courtney, Vincent Kalish, Frederick Brookfield, Lisa Frost, John Toscano

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Therapeutic Matter, Therapeutic Substance Synthesis Method, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure

Bis-Acylated Hydroxylamine Derivatives as Physiologically Useful HNO Donors

Technology OverviewThe invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing,...

Published: 5/9/2024 | Inventor(s): Frederick Brookfield, Vincent Kalish, Lisa Frost, Art Sutton, Stephen Courtney, John Toscano

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Therapeutic Matter, Therapeutic Substance Synthesis Method, Therapeutics

N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors

Technology OverviewThe invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide...

Published: 5/9/2024 | Inventor(s): Lisa Frost, Vincent Kalish, Andrew Cohen, Frederick Brookfield, Stephen Courtney, John Toscano

Keywords(s): Cardiovascular Diseases, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

N-Hydroxysulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors

Technology OverviewThe invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide...

Published: 5/9/2024 | Inventor(s): Andrew Cohen, Frederick Brookfield, Vincent Kalish, Stephen Courtney, Lisa Frost, John Toscano

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure

Diazen-1-ium-1, 2-diolate Derivatives as New Nitroxyl Donors

Unmet NeedHeart failure is a continuously growing health issue in the United States. According to a study by the CDC, approximately 6.2 million Americans had heart failure between the years 2013-2016, and that number is expected to breach 8 million by 2030 (see AHA). Acute decompensated heart failure (ADHF), a potentially fatal cause of respiratory...

Published: 5/9/2024 | Inventor(s): Christopher Pavlos, Preeya Kapur Boppana, John Toscano

Keywords(s): Basic Research Biomarker, Discovery/Research Tools, Enzymes, Recombinant Proteins, Research Reagent

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools

N-Substituted Hydroxylamine Derivatives with Carbon-Based Leaving Groups as Physiologically Useful Nitroxyl (HNO) Donors

Technology OverviewThe disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions...

Published: 5/9/2024 | Inventor(s): Daryl Guthrie, John Toscano

Keywords(s): Cardiovascular Diseases, Disease Indication, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Therapy Type

O‐substituted hydroxamic acids with pyrazolone leaving groups as novel physiologically useful HNO donors

#C14009Inventor(s): John Toscano, Saghar Nourian, Daryl Guthrie Unmet NeedAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn't until 2003 that scientists realized the beneficial...

Published: 5/9/2024 | Inventor(s): John Toscano, Saghar Nourian, Daryl Guthrie

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure

N-hydroxylsulfonamide Derivatives as Nitroxyl Donors

#C13855Inventor(s): John Toscano, Vincent Kalish, Lisa Frost, Frederick Brookfield, Stephen CourtneyUnmet NeedAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn't until 2003...

Published: 5/9/2024 | Inventor(s): John Toscano, Vincent Kalish, Lisa Frost, Frederick Brookfield, Stephen Courtney

Keywords(s): Cardiovascular Diseases, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

New N-substituted Hydroxamic Acids with Carbon-based Leaving Groups as Efficient HNO Donors

#C13661Inventor(s): John Toscano, Saghar NourianUnmet NeedAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn't until 2003 that scientists realized the beneficial effect was due...

Published: 5/9/2024 | Inventor(s): John Toscano, Saghar Nourian

Keywords(s): Cardiovascular Diseases, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities

1 2